Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2012 Jul 19;32(9):2122–2130. doi: 10.1161/ATVBAHA.112.253435

Omega-3 Fatty Acids Ameliorate Atherosclerosis by Favorably Altering Monocyte Subsets and Limiting Monocyte Recruitment to Aortic Lesions

Amanda L Brown 1, Xuewei Zhu 1, Shunxing Rong 1, Swapnil Shewale 1, Jeongmin Seo 1, Elena Boudyguina 1, Abraham K Gebre 1, Martha A Alexander-Miller 3, John S Parks 1,2,*
PMCID: PMC3431287  NIHMSID: NIHMS399435  PMID: 22814747

Abstract

Objective

Fish oil (FO), containing n-3 fatty acids (FAs), attenuates atherosclerosis. We hypothesized that n-3 FA-enriched oils are atheroprotective through alteration of monocyte subsets and their trafficking into atherosclerotic lesions.

Methods and Results

Low density lipoprotein receptor knockout (LDLr−/−) and apolipoprotein E−/− (apoE) mice were fed diets containing 10% (calories) as palm oil (PO) and 0.2% cholesterol, supplemented with an additional 10% PO, echium oil (EO; containing 18:4 n-3) or FO. Compared to PO-fed LDLr−/− mice, EO and FO significantly reduced plasma cholesterol, splenic Ly6Chi monocytosis by ~50%, atherosclerosis by 40–70%, monocyte trafficking into the aortic root by ~50%, and atherosclerotic lesion macrophage content by 30–44%. In contrast, atherosclerosis and monocyte trafficking into the artery wall was not altered by n-3 FAs in apoE−/− mice; however, Ly6Chi splenic monocytes positively correlated with aortic root intimal area across all diet groups. In apoE−/− mice, FO reduced the percentage of blood Ly6Chi monocytes, despite an average two-fold higher plasma cholesterol relative to PO.

Conclusions

The presence of splenic Ly6Chi monocytes parallels the appearance of atherosclerotic disease in both LDLr−/− and apoE−/− mice. Furthermore, n-3 FAs favorably alter monocyte subsets independently from effects on plasma cholesterol, and reduce monocyte recruitment into atherosclerotic lesions.

Keywords: monocytosis, n-3 fatty acids, fish oil, Echium oil, inflammation, Ly6C


Omega-3 fatty acids (n-3 FAs) are atheroprotective molecules1–3 that exert potent triglyceride-lowering effects in animals and humans4, 5. But in humans, n-3 FAs rarely affect plasma cholesterol levels, the primary factor leading to atherosclerosis5, 6. However, atherosclerosis has a marked inflammatory component, making it necessary to understand how the anti-inflammatory properties of n-3 FAs7–9 impact this disease. Thus, we sought to elucidate other potential mechanisms by which n-3 FAs reduce atherosclerosis, directing attention to their anti-inflammatory properties.

n-3 FAs reportedly reduce macrophage staining in atherosclerotic plaques in animal models of atherosclerosis and humans10–12, suggesting a potential mechanism by which n-3 FAs exhibit atheroprotection, because of the critical role macrophages, and their precursor monocytes, play in this disease13–15. The accumulation of blood monocytes in the artery wall correlates with lesion development and there is constant influx of these cells into developing plaques throughout the progression of atherosclerosis16.

Two major subclasses of monocytes have been identified in mammals17, 18, designated classical and nonclassical monocytes. They are differentiated by a number of cell surface receptors in mice, including CCR2, CX3CR1, CD62L, CD11c and Ly6C. Ly6Chi classical monocytes co-express CCR2 and CD62L, and are actively recruited to sites of inflammation. In contrast, Ly6Clo nonclassical monocytes express higher levels of CX3CR1 and CD11c compared to Ly6Chi cells. This population patrols the circulation, eventually entering tissues to replenish resident dendritic cells and macrophages17. Recent studies suggest that Ly6Chi monocytes increase in hyperlipidemic apoE−/− mice, and migrate into atherosclerotic plaques to become lesional macrophages 19–21. However, Ly6Clo monocytes, which preferentially express CD11c, may also contribute to atherogenesis by accumulating lipids in the circulation and transporting them to the developing plaque22. Thus, both monocyte subsets have the potential to impact atherosclerosis.

We hypothesized that n-3 FAs would reduce atherosclerosis and concomitantly alter monocyte subsets and monocyte recruitment to the developing lesion. We tested this hypothesis using botanical and marine sources of n-3 FAs in two well-characterized mouse models of atherosclerosis, low density lipoprotein receptor knockout (LDLr−/−) and apolipoprotein E knockout (apoE−/−) mice. Furthermore, we also sought to determine whether hypercholesterolemia-associated monocytosis of Ly6Chi cells occurs in the LDLr−/− background, as has been described in apoE−/−, and whether n-3 FAs could inhibit this process.

Methods

Mice and diets

LDLr−/− and apoE−/− mice (C57BL/6 background) were purchased from The Jackson Laboratory (Bar Harbor, Maine, USA). Mice were housed in a specific pathogen-free facility with a 12-hour light/dark cycle. All protocols and procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Wake Forest School of Medicine. At six to eight weeks of age, female mice were fed atherogenic diets containing 10% calories as PO and 0.2% cholesterol, supplemented with an additional 10% of calories as palm oil (PO), echium oil (EO; containing 18:4 n-3) or fish oil (FO) for 16 (LDLr−/−) or 12 (apoE−/−) weeks. See supplemental methods for detailed description of the oils. The synthetic diets were prepared by the diet kitchen in the Department of Pathology at Wake Forest School of Medicine as previously described23. The fatty acid composition of the PO, EO and FO diets has been previously published24. A standard chow diet, Prolab IsoPro RMH 3000 (LabDiet) was used as an additional control.

Quantification of aortic root lesion area

The aortic root was sequentially sectioned following an adaptation of the method of Daugherty et al25. Once the aortic valves were visible, 8-μm aortic root sections were retained for the length of 640 μm. The sections were placed on a series of 10 slides. This resulted in 8 sections per slide, with a distance of 80 μm apart. Oil red O and hematoxylin staining was performed to assist in tissue visualization. Images were acquired with a Nikon DigitalSight DSFi1 camera using NIS Elements (Nikon) software. Intimal area measurements were obtained with ImagePro 6.2 software (Media Cybernetics). We defined intimal area as the lesion area between the internal elastic lamina and the luminal surface of the aorta. Three 8-μm aortic root sections were blindly quantified from each mouse, from a single slide. Sections were examined in the aortic root starting from the proximal region (when the three aortic valves appear) and proceeding distally, unless a section was deemed immeasurable, due to a fold, tear, etc. in which case the adjacent section was measured. The mean coefficient of variation for these measurements from individual mice on atherogenic diets was 10.7%.

Plasma lipid and lipoprotein analyses

Blood was collected by submandibular vein puncture in non-fasted mice in the presence of heparin. Plasma from these blood samples was isolated using a table top centrifuge (10,000 rpm for 15 min at 4°C). Plasma cholesterol or triglyceride concentrations were measured enzymatically using commercially available kits (Wako). Plasma lipoproteins were fractionated by fast protein liquid chromatography (FPLC) and cholesterol distribution among lipoproteins was measured by enzymatic assay26.

Flow cytometry

Peripheral blood was obtained by submandibular vein puncture for circulating leukocyte analysis. For splenic cells, tissue was digested with an enzyme cocktail as published27. The cell suspension was subsequently passed through a 70-μm nylon cell strainer (BD Falcon). Red blood cells were removed from flow cytometry preparations by treatment with ACK lysing buffer (Gibco). The remaining white blood cells were incubated with the following mAbs: CD11b-APC-Cy7 clone:M1/70 (BioLegend), CD115-APC clone:AFS98, CD62L-PerCP-Cy5.5 clone:MEL-14 (eBiosciences), Ly6G-PE clone:1A8, CD11c-PE-Cy7 clone:HL3, Ly6C-FITC or PE clone:AL-21 (BD Pharmingen). Data were acquired on a BD FACSCanto II instrument (BD Biosciences) and analyzed using FacsDiva software (BD Biosciences).

Monocyte labeling and quantification of monocyte recruitment

Monocytes were labeled using the Gr-1lo method of Tacke et al28. Briefly, 1-μm Fluoresbrite Yellow Green (YG) microspheres (2.5% solids [wt/vol], Polysciences, Inc.) were diluted 1:4 in PBS and injected retro-orbitally into anesthetized mice. Blood was drawn from recipient mice the day after labeling to evaluate the total number of bead-containing monocytes per mouse. This approach predominantly labels Ly6Clo monocytes, although some transient labeling of Ly6Chi monocytes has been observed28.

Aortic root tissue sections were taken as described above and the number of beads confined to atherosclerotic lesions was quantified per section. A total of 8 sections, from a single slide, representative of the length of the aortic root, were analyzed per mouse. Beads were counted manually, at 20X magnification. To adjust for slight variations in labeling, data were normalized for individual mice based on the percentage of blood monocytes labeled. For example, if an individual mouse had 11% of blood monocytes labeled, and 15 bead-containing cells per section were counted, the calculation would be as follows 15/0.11 = 136. This adjustment gave a normalized value, which represented the actual number of monocytes expected to have entered the lesion.

Immunohistochemistry

Aortic roots were mounted in OCT and sectioned as described under the quantification of aortic root lesion area section of the methods. Aortic root cross-sections were fixed with acetone and incubated with an anti-CD68 antibody (1:75, overnight) from AbD Serotec (clone:FA11), followed by staining with an alkaline phosphatase-conjugated secondary antibody (goat anti-rat, 1:50, 30 minutes) from AbD Serotec; control slides contained no primary antibody. Four 8-μm aortic root sections from each mouse were blindly analyzed for the percent CD68-positive area.

Statistical analyses

All data were subjected to parametric analysis and passed the D’Agostino and Pearson omnibus normality test. Data are presented as mean ± SEM and were tested for significant differences (p< 0.05) using 1-way ANOVA with Tukey’s post-hoc analysis. Pearson’s correlation coefficient was calculated after the line of best fit was determined using linear regression analysis. All the analyses were performed with GraphPad Prism 5.01 (GraphPad Software Inc., San Diego, CA).

Results

n-3 FAs reduced atherosclerosis in LDLr−/−, but not apoE−/− mice

As previously described23, 29, n-3 FAs reduced atherosclerosis development in LDLr−/− mice (Figure 1A and 1B). We observed a stepwise decrease in atherosclerosis that correlated with the degree of enrichment of long chain n-3 FAs following either EO or FO supplementation for 16 weeks24. Standard rodent chow has negligible amounts of cholesterol, and as expected, this group had the lowest intimal lesion area. Interestingly, parallel studies in apoE−/− mice resulted in no difference in atherosclerosis among diet groups after 12 weeks of diet consumption (Figure 1A and 1C). As expected, apoE−/− chow-fed mice had reduced atherosclerosis compared to mice fed atherogenic diets. We also measured aortic cholesterol content in the entire aorta (arch, thoracic, abdominal) in LDLr−/− and apoE−/− mice and observed similar trends as with aortic root intimal area (Supplemental Figure 1A and 1B). Furthermore, aortic root intimal area positively correlated with aortic cholesterol ester content in mice of both backgrounds (Supplemental Figure 1C and 1D). Thus, dietary n-3 FAs reduced atherosclerosis in LDLr−/−, but not apoE−/− mice.

Figure 1.

Figure 1

Dietary n-3 FAs reduce atherosclerosis in LDLr−/−, but not apoE−/− mice. At six to eight weeks of age, female mice were fed chow or diets containing 10% calories as PO and 0.2% cholesterol, supplemented with an additional 10% of calories as PO, EO or FO for 16 (LDLr−/−) or 12 (apoE−/−) weeks. A. Representative photomicrographs of Oil Red O and hematoxylin-stained cross-sections of the aortic root (4X magnification). Quantitative analysis of aortic root intimal area in LDLr−/− (B) or apoE−/− mice (C). Data points shown in panels B and C represent individual mice; the horizontal line denotes the group mean. Values not sharing a common superscript differ significantly (p<0.05).

Differential plasma cholesterol responses to diet in LDLr−/− and apoE−/− mice

In agreement with previous reports23, 29, n-3 FAs blunted hypercholesterolemia in the LDLr−/− mice (Figure 2A and 2C), with equivalent reductions in EO and FO-fed mice compared to PO-fed mice. Plasma cholesterol measurements in apoE−/− mice uncovered an unexpected finding (Figure 2B). The FO-fed mice had the highest exposure to cholesterol over time as illustrated using area under the curve (AUC) analysis for total plasma cholesterol, with all other groups exhibiting similar levels (Figure 2D). FPLC size fractionation of plasma revealed that the increase in total plasma cholesterol concentrations in the FO diet group was primarily due to an increase in VLDL-size particles (Supplemental Figure 2B). There is one other report of an increase in plasma cholesterol in n-3 FA-fed apoE−/− mice29. Plasma triglyceride concentrations increased in FO vs. PO-fed apoE−/− mice (64±6 vs. 22±7 mg/dL, respectively; n=7–9 per group), consistent with previous reports11, 29–33. Thus, differential plasma cholesterol and triglyceride responses to diet were observed in LDLr−/− and apoE−/− mice.

Figure 2.

Figure 2

Differential plasma cholesterol responses to diet were observed in LDLr−/− and apoE−/− mice. At six to eight weeks of age, female mice were fed chow or diets containing 10% calories as PO and 0.2% cholesterol, supplemented with an additional 10% of calories as PO, EO or FO for 16 (LDLr−/−) or 12 (apoE−/−) weeks. A. Enzymatic analysis of total plasma cholesterol in LDLr−/− mice. B. Enzymatic analysis of total plasma cholesterol in apoE−/− mice. Area under the curve (AUC; i.e., concentration vs. time) for individual mice was calculated for plasma cholesterol concentrations in LDLr−/− (C) or apoE−/− mice (D). Data shown in panels A-D represent the mean ± SEM for 6–10 mice per group; values not sharing a common superscript differ significantly (p<0.05). E. Linear regression analysis of aortic root intimal area vs. plasma cholesterol AUC for LDLr−/− (E) or apoE−/− (F) mice. In panels E and F, each point represents an individual animal of the denoted diet group and the correlation coefficient is shown for entire data set (E).

Plasma cholesterol does not correlate with disease burden in apoE−/− mice

Atherosclerosis was similar among PO, EO, and FO-fed apoE−/− mice (Figure 1C, Supplemental Figure 1B), despite two-fold higher plasma cholesterol AUC in the FO group (Figure 2D). Furthermore, linear regression analysis demonstrated a significant association between intimal area and plasma cholesterol in the LDLr−/− (Figure 2E), but not in apoE−/− mice (Figure 2F). These results suggest a unique property of FO that counterbalanced the hypercholesterolemia induced by FO feeding in apoE−/− mice to promote atherosclerosis progression.

n-3 FAs favorably alter Ly6Chi monocytes in atherosclerotic mice

Despite a substantial lowering of triglycerides6, 34, n-3 FAs typically do not alter plasma cholesterol in humans and may, in fact, increase LDL cholesterol and lower HDL cholesterol in some individuals5, 6. We investigated the possibility that n-3 FAs could reduce the Ly6Chi monocyte subset, which infiltrate into atherosclerotic lesions20, since reduced macrophage staining has been reported with n-3 fatty acid supplementation10–12. We identified monocytes as CD11b+Ly6G−CD115+ (Supplemental Figure 3A). In agreement with other findings18, 20, 21, Ly6Chi cells preferentially expressed CD62L, whereas CD11c expression was found primarily on Ly6Clo monocytes (Supplemental Figure 3B). We observed no significant difference in the percentage of monocytes in the circulation of LDLr−/− mice during the 16-week atherosclerosis progression experiment based on atherogenic diet fat type, although chow-fed mice had significantly less monocytosis compared to PO and EO-fed mice (Supplemental Figure 4A and C). In agreement with another 12-week study in apoE−/− mice19, the saturated fat-containing atherogenic diet (i.e., PO) did not significantly alter the percentage of monocytes in the circulation compared to chow-fed controls (Supplemental Figure 4B and D). However, using AUC analysis, we did observe an increase in percentage of monocytes in FO-fed mice compared to PO and chow-fed mice (Supplemental Figure 4D). With regard to subset distribution, the proportion of monocytes in the Ly6Chi subset was not altered over 16 weeks in LDLr−/− mice (Supplemental Figure 4E). However, after 12 weeks of experimental diet feeding both FO and chow-fed apoE−/− mice showed a reduction in the Ly6Chi subset compared to PO-fed mice, indicating a more favorable monocyte profile (Supplemental Figures 3A and 4F).

The inflammatory profile of splenic monocytes parallels atherosclerosis

The percentage of monocytes in the spleen, identified as a reservoir for circulating monocytes35, was similar among diet groups in LDLr−/− and apoE−/− mice (Figure 3B and 3C). However, in the LDLr−/−, n-3 FAs from EO and FO reduced the Ly6Chi subset to levels of chow-fed mice (Figure 3A and 3D). In the apoE−/− background, only the mice fed chow were different than the PO group (Figure 3E). In fact, the changes in the Ly6Chi subset were strikingly similar to changes in intimal lesion area (compare Figures 3E and 1C). Furthermore, we found a significant positive association between percentage of Ly6Chi splenic monocytes and intimal area in both LDLr−/− and apoE−/− mice (Figure 3F and Figure 3G).

Figure 3.

Figure 3

Splenic Ly6Chi monocytes correlate with atherosclerosis. Live spleen cells were gated using forward and side scatter characteristics and further identified as monocytes by expression of CD11b and CD115. A. Representative histograms from the indicated diet groups. CD11b+Ly6G−CD115+ monocytes were analyzed for expression of Ly6C after 16 weeks on diet in LDLr−/− mice. Percentages of Ly6Chi monocytes are shown as mean ± SEM. The percentage of monocytes in the spleen was calculated for LDLr−/− (B) and apoE−/− (C) mice after 16 and 12 weeks on diet, respectively. The percentage of monocytes in the Ly6Chi subset was measured in the spleen of LDLr−/− (D) and apoE−/− (E) mice after 16 or 12 weeks on diet, respectively. Data shown in panels BE represent individual mice with the group mean denoted by the horizontal line; values not sharing a common superscript differ significantly (p<0.05). Panels lacking superscripts indicate statistical differences among groups were not observed at p=0.05. F. Linear regression analysis of aortic root intimal area vs. percentage of splenic monocytes of the Ly6Chi subset for LDLr−/− (F) or apoE−/− (G) mice. In panels F and G, each point represents an individual animal of the denoted diet group and the correlation coefficient is shown for entire data set.

n-3 FAs protect against neutrophilia in hypercholesterolemic mice

Recent advances in the field have also highlighted the importance of hypercholesterolemia-induced neutrophilia in atherosclerosis36. We measured blood neutrophils in LDLr−/− and apoE−/− mice after 16 and 12 weeks on atherogenic diets, respectively (Supplemental Figure 5A and 5B). Just as n-3 FAs dissociated hypercholesterolemia from Ly6Chi monocytosis, we also observed dissociation of hypercholesterolemia from neutrophilia after 16 weeks in the LDLr−/− mice, where n-3 FAs reduced blood neutrophils to levels of chow-fed mice. In apoE−/− mice, we detected a decrease in neutrophils with both EO and FO fed mice after 6 and 9 weeks on diet. Similar findings were observed in the spleen (Supplemental Figure 5C and 5D), a compartment that may reflect cumulative effects of dietary FAs on systemic neutrophil levels.

n-3 FAs reduce monocyte infiltration into atherosclerotic lesions

To determine whether n-3 FAs would decrease monocyte trafficking into atherosclerotic lesions, we performed monocyte-labeling experiments after maintaining LDLr−/− or apoE−/− mice on diet for 16 or 12 weeks, respectively. Using the procedure developed by Randolph and colleagues21, 28, we phagocytically labeled monocytes with 1μm fluorescent beads. Within 24 hrs of injection, 0.7–1.2% of blood leukocytes were labeled in the LDLr−/− diet groups, and 1.0–1.2% of blood leukocytes were labeled in the apoE−/− groups. Of these bead+ cells, 63–81% (mean, 79.4%) were monocytes in LDLr−/− mice, and 78–90% (mean, 85.3%) were monocytes in the apoE−/−. This translated to 6.5–13.3% (mean, 9%) of monocytes carrying a fluorescent label in LDLr−/− mice. In apoE−/− mice, 6.0–11.6% (mean, 8%) of monocytes were bead+. The remainder of bead-labeled non-monocytic cells in blood were B cells (CD19+; 66%) and neutrophils (Ly6-G+; 34%), similar to previous findings using this technique28.

The number of recruited monocytes (visualized as fluorescent beads, see Supplemental Figure 6) within the lesion area of the aortic root in mice fed PO, EO, or FO diets was compared to chow-fed controls in LDLr−/− mice (Figure 4A) and apoE−/− mice (Figure 4B). Because of slight variations in labeling (6.5–13.3% in LDLr−/− mice, 6.0–11.6% in apoE−/−), data were normalized for individual mice based on the percentage of blood monocytes labeled. This adjustment gave a normalized value, which represented the actual number of monocytes entering the lesion (i.e. normalized frequency). Normalization revealed a decrease in bead+ cells per intimal area per section in all groups compared to PO in LDLr−/− mice (Figure 4C). In contrast, bead+ monocytes did not differ among diet groups in the apoE−/− background (Figure 4D), although there was a trend towards a decrease in chow vs. PO-fed mice. Of interest, numbers of monocytes trafficking to lesions were higher in the apoE−/− compared to the LDLr−/− (compare scales Figure 4A and 4C versus 4B and 4D), perhaps reflecting the heightened inflammatory response in the apoE−/− model37, 38. Together these data indicate that n-3 FAs reduce infiltration of monocytes into atherosclerotic lesions to an extent related to the amount of atherosclerosis.

Figure 4.

Figure 4

N-3 FAs reduce infiltration of monocytes into atherosclerotic lesions. Labeled monocyte trafficking to the aortic root lesion area in LDLr−/− (A) or apoE−/− (B) mice after 16 or 12 weeks on diet, respectively, was quantified as beads per section. Each bead represents a labeled monocyte. Panels C and D show normalized data adjusted for individual animal differences in the percentage of labeled monocytes in the circulation of LDLr−/− or apoE−/− mice, respectively. Values not sharing a common superscript differ significantly, and panels lacking superscripts indicate statistical differences were not observed at p=0.05.

n-3 FAs decrease macrophage staining in atherosclerotic lesions

In concordance with our monocyte infiltration data, analysis of CD68 immunohistochemistry in LDLr−/− mice (Figure 5A and 5B) revealed that n-3 FA-fed mice exhibit reduced (30–44%) macrophage staining compared to PO-fed mice, equivalent to chow-fed mice.

Figure 5.

Figure 5

Dietary n-3 FAs reduce CD68+ macrophage staining in lesions of LDLr−/− mice after 16 weeks on diet. A. Representative photomicrographs of CD68 immunostained cross-sections of the aortic root (20X magnification). B. Quantitative analysis of CD68+ positive intimal area in LDLr−/− mice. Data shown in panel B represent the mean ± SEM from 6–10 mice per group, and values not sharing a common superscript differ significantly (p<0.05).

Discussion

n-3 FAs have been appreciated as cardioprotective molecules for decades39. Much of the focus regarding their mode of action has been centered on plasma lipid-lowering effects4, 5, 40. However, in humans, n-3 FAs rarely have an effect on plasma cholesterol levels, a bona fide promoter of atherosclerosis5, 6. Thus, we sought to elucidate other potential mechanisms by which n-3 FAs reduce atherosclerosis, directing our attention to their anti-inflammatory properties41. We used LDLr−/− mice to examine development of hypercholesterolemia-associated monocytosis and neutrophilia, in studies not previously performed in this model. Employing the apoE−/− model enabled us to compare the relative contributions of non-plasma cholesterol parameters, such as monocyte phenotype, on atherosclerosis outcome, since in apoE−/− mice, n-3 FAs did not reduce plasma cholesterol, and even increased it in the case of FO.

As anticipated, dietary n-3 FAs reduced atherosclerosis in LDLr−/− mice. Reductions in plasma cholesterol are a potential mechanism for the decrease in atherosclerosis. Indeed, both EO and FO reduced total plasma cholesterol to a similar level over the 16-week study (Figure 2A and 2C); however, FO-fed mice had significantly lower aortic root intimal area compared to those fed EO (Figure 1B). We attribute this to the higher levels of atheroprotective n-3 FAs in FO-fed mice compared to EO-fed mice, particularly DHA24. Therefore, even in the LDLr−/− mouse, in which n-3 FAs are associated with consistently lower plasma lipids, we have evidence that n-3 FAs reduce atherosclerosis independently of plasma lipid reduction. Nonetheless, based on linear regression analysis in the LDLr−/− mice, approximately 70% of the variability in atherosclerosis can be explained by plasma cholesterol levels (Figure 2E). Thus, in this model, it is difficult to state with certainty that reductions in atherosclerosis and changes in monocyte subset distribution are due to the anti-inflammatory potential of n-3 FAs versus their hypolipidemic properties.

Our findings in apoE−/− mice allow for different interpretations because dietary fat did not lower plasma cholesterol. Interestingly, only chow-fed mice had reduced atherosclerosis compared to PO-fed mice. However, this could not be ascribed to significantly decreased exposure to cholesterol over time in chow-fed versus PO-fed mice (Figure 2B and 2D). In fact, no significant correlation between atherosclerosis and plasma cholesterol was observed in apoE−/− mice (Figure 2F). By contrast, the FO group had twice the plasma cholesterol exposure as their PO-fed counterparts (Figure 2D), yet similar atherosclerosis compared to PO-fed mice (Figure 1C). This illustrates that n-3 FAs can moderate atherosclerosis apart from effects on plasma cholesterol, as has been consistently reported in humans5, 6.

Changes in plasma lipids, namely triglycerides, were not expected with n-3 FAs in apoE−/− mice because apoE is thought to play an important role in the increased clearance of triglyceride-rich lipoproteins that occurs with n-3 FA treatment11, 29–33, 42, 43. Furthermore, increases in cholesterol were not expected and have not been frequently reported29. Likely, the elevated cholesterol levels in FO-fed animals can be attributed to decreased activity of the LDL receptor clearance pathway. Our group and others have noted a decrease in LDL receptor activity and binding affinity of lipoproteins following FO feeding44–46. Thus, because of the role of the LDL receptor in clearing remnant particles47, any alterations could have a profound effect in the apoE−/− model, in which plasma remnant particles are elevated. Thus, in apoE−/− mice, where the LDL receptor pathway is intact, FO may reduce the clearance of remnant particles, resulting in an increase in cholesterol compared to PO-fed controls.

Our data indicated that factors other than plasma lipids contribute to the anti-atherogenic properties of n-3 FAs. Therefore, we tested the hypothesis that n-3 FAs could alter Ly6C monocyte subsets, which have important implications in atherosclerosis19–21, 48. In the LDLr−/− mice, analysis of the expression of Ly6C on blood monocytes showed similar subset distribution among diet groups. In contrast, apoE−/− mice exhibited a decrease in the Ly6Chi subset to levels of chow-fed mice, despite the high plasma cholesterol observed with FO feeding. This finding suggests that Ly6Chi monocytosis can be dissociated from hypercholesterolemia, particularly in the context of reduced inflammation, as would be expected with n-3 FA supplementation.

Since the spleen can serve as a reservoir for monocytes in the periphery35 and may reflect cumulative changes during dietary treatment, we assessed this compartment for the effects of n-3 FAs. Proportions of total monocytes in the spleen did not change as a function of dietary fat in either LDLr−/− or apoE−/− mice. However, contrary to the blood monocyte data, n-3 FAs reduced the Ly6Chi subset compared to PO to the level of chow-fed mice in the LDLr−/− model. This is likely due to the fact that blood monocytes represent a transient pool of cells that turn over rather quickly, whereas the spleen reflects what may be occurring in the body over time. Furthermore, in both LDLr−/− and apoE−/− mice, the Ly6Chi profile of splenic monocytes did not appear to correlate with plasma cholesterol measurements, but instead with atherosclerosis. Interestingly, in the apoE−/− mice, the changes in the Ly6Chi subset paralleled lesion area more closely than did plasma cholesterol. Our data with blood and splenic neutrophils resulted in a similar conclusion as we also observed reductions in this cell type in EO and FO-fed mice compared to PO-fed mice that were not reflective of changes in hypercholesterolemia per se. These observations support the notion that monocyte distribution skewing towards the Ly6Chi subset, as well as neutrophilia, correlate better with atherosclerosis disease burden than cholesterol levels.

We also sought to determine whether decreased macrophage abundance in atherosclerotic lesions following n-3 FA treatment11, 12, 34 is due to decreased monocyte trafficking. We observed decreased recruitment of monocytes to plaques coupled with decreased macrophage staining in EO, FO, and chow-fed mice compared to PO-fed LDLr−/− mice, suggesting that monocyte trafficking could be the reason for fewer macrophages in lesions following n-3 fatty acid treatment. The finding that omega-3 fatty acid supplementation reduces monocyte recruitment to lesions is important because recent evidence suggests that decreased monocyte recruitment leads to regression of atherosclerotic disease49.

Overall, our data support the notion that n-3 FAs reduce atherosclerosis, in part, by favorably altering monocyte subsets and reducing trafficking of monocytes to atherosclerotic plaques. In addition, several points from this study and others converge to make an argument for the Ly6Chi monocyte profile as a relevant marker for disease progression as opposed to plasma cholesterol. First, cholesterol feeding of wild-type mice increases plasma cholesterol, yet these animals do not develop monocytosis or exhibit changes in the distribution of Ly6C monocytes20, 21. Second, although results observed following statin treatment have been used to support an association between hypercholesterolemia and Ly6Chi monocytosis20, statins have known immunomodulatory and anti-inflammatory properties50, 51 that could impact blood monocyte numbers and subset distribution. Furthermore, any treatment (such as statin therapy) that alters plasma cholesterol will impact atherosclerotic disease progression, making it impossible to conclude that alterations in plasma cholesterol alone are affecting Ly6Chi monocytosis. Third, in our studies, hypercholesterolemia, monocytosis, and the distribution of the Ly6C subset do not correlate across time. Using LDLr−/− mice as an example, plasma cholesterol peaks around 4 weeks of dietary intervention, yet the blood monocytes gradually increase over 16 weeks. In further support of this, plasma cholesterol was not related to the percentage of Ly6Chi monocytes in the circulation or the spleen in either LDLr−/− or apoE−/− mice. Interestingly, plasma cholesterol in EO and FO-fed mice was intermediate between PO and chow-fed controls in the LDLr−/− background, yet splenic Ly6Chi monocytes and monocyte trafficking were reduced to the extent of chow-fed mice, further supporting the idea that beneficial effects on Ly6Chi monocytosis are independent of alterations in plasma cholesterol.

It is noteworthy that the beneficial effects of anti-inflammatory n-3 fatty acids were partially blunted in apoE−/− mice, which generally exhibit a higher inflammatory state than LDLr−/− mice37, 38. Part of this blunted response may be related to the absence of plasma lipid-lowering by n-3 FAs in apoE−/− mice30. In addition, apoE is a critical component of the macrophage sterol-responsive network in macrophage foam cells and is upregulated in the artery wall by atheroprotective substances, such as thiazolidinediones and statins52. In the absence of apoE, the beneficial effects of n-3 FA on reducing macrophage inflammation and foam cell formation may be partially lost.

Future studies may examine whether any of the mechanisms described in this current study could occur through fatty acid sensors such as the recently discovered GPR120 receptor9. This receptor regulates the ability of n-3 FAs to decrease M1 proinflammatory gene expression and increase M2 inflammatory gene expression. It is plausible that GPR120 plays an additional role in the alterations of Ly6C monocyte subsets observed with n-3 fatty acid treatment. Another potential mechanism might involve n-3 fatty acid regulation of low-density lipoprotein receptor-related protein 1, which has recently been shown to decrease Ly6Chi monocytosis in an apoE independent fashion53.

In conclusion, n-3 FAs reduce atherosclerosis, alter monocyte subsets, and reduce monocyte trafficking to atherosclerotic lesions of LDLr−/− mice. The combination of fewer circulating Ly6Chi monocytes and a reduced percentage of circulating neutrophils maintained atherosclerotic disease burden in apoE−/− mice fed n-3 fatty acids to levels comparable to those fed saturated fat, despite the two-fold higher plasma cholesterol exposure in the FO group. Reductions in atherosclerosis in LDLr−/− mice likely occurred through similar mechanisms, with the additional benefit that n-3 FAs decreased monocyte recruitment to the artery wall. Finally, our data provide evidence that the inflammatory profile of splenic monocytes parallels atherosclerosis, as opposed to plasma cholesterol levels. This finding has important implications regarding the interactions between hyperlipidemia and innate immunity in the context of atherosclerosis, and should be considered when evaluating the impact of hyperlipidemia on immune cells in models of atherosclerosis.

Supplementary Material

Acknowledgments

Omega Protein Inc. provided OmegaPure refined menhaden oil for the FO diet groups and Croda Chemicals provided the Echium plantagenium oil used in these studies. The authors thank Drs. Gwendolyn J. Randolph (Washington University, St. Louis, MO) and Molly A. Ingersoll for assistance with flow cytometry and monocyte labeling techniques. We gratefully acknowledge Karen Klein (Research Support Core, Wake Forest School of Medicine) for editing the manuscript.

Funding Sources: This work was funded by grant numbers P50AT002782, R01HL094525, and P01HL049373 to JSP and F31AT004883 to ALB.

Footnotes

Disclosures: John S. Parks is a member of the Merck Speaker bureau and a consultant for GlaxoSmithKline.

References

  • 1.Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial (dart) Lancet. 1989;2:757–761. doi: 10.1016/s0140-6736(89)90828-3. [DOI] [PubMed] [Google Scholar]
  • 2.Daviglus ML, Stamler J, Orencia AJ, Dyer AR, Liu K, Greenland P, Walsh MK, Morris D, Shekelle RB. Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med. 1997;336:1046–1053. doi: 10.1056/NEJM199704103361502. [DOI] [PubMed] [Google Scholar]
  • 3.Hu FB, Bronner L, Willett WC, Stampfer MJ, Rexrode KM, Albert CM, Hunter D, Manson JE. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA. 2002;287:1815–1821. doi: 10.1001/jama.287.14.1815. [DOI] [PubMed] [Google Scholar]
  • 4.Parks JS, Rudel LL. Effect of fish oil on atherosclerosis and lipoprotein metabolism. Atherosclerosis. 1990;84:83–94. doi: 10.1016/0021-9150(90)90077-v. [DOI] [PubMed] [Google Scholar]
  • 5.Harris WS. Fish oils and plasma lipid and lipoprotein metabolism in humans: A critical review. J Lipid Res. 1989;30:785–807. [PubMed] [Google Scholar]
  • 6.Nestel PJ, Connor WE, Reardon MF, Connor S, Wong S, Boston R. Suppression by diets rich in fish oil of very low density lipoprotein production in man. J Clin Invest. 1984;74:82–89. doi: 10.1172/JCI111422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Oh SF, Pillai PS, Recchiuti A, Yang R, Serhan CN. Pro-resolving actions and stereoselective biosynthesis of 18s e-series resolvins in human leukocytes and murine inflammation. J Clin Invest. 2011;121:569–581. doi: 10.1172/JCI42545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC, Rimm EB. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among us men and women. Circulation. 2003;108:155–160. doi: 10.1161/01.CIR.0000079224.46084.C2. [DOI] [PubMed] [Google Scholar]
  • 9.Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, Olefsky JM. Gpr120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142:687–698. doi: 10.1016/j.cell.2010.07.041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, Gallagher PJ, Calder PC, Grimble RF. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: A randomised controlled trial. Lancet. 2003;361:477–485. doi: 10.1016/S0140-6736(03)12468-3. [DOI] [PubMed] [Google Scholar]
  • 11.Matsumoto M, Sata M, Fukuda D, Tanaka K, Soma M, Hirata Y, Nagai R. Orally administered eicosapentaenoic acid reduces and stabilizes atherosclerotic lesions in apoe-deficient mice. Atherosclerosis. 2008;197:524–533. doi: 10.1016/j.atherosclerosis.2007.07.023. [DOI] [PubMed] [Google Scholar]
  • 12.Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJ, Gudmundsen O, Vige R, Payne SP, Ye S, Shearman CP, Gallagher PJ, Grimble RF, Calder PC. Eicosapentaenoic acid (epa) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque epa is associated with decreased plaque inflammation and increased stability. Atherosclerosis. 2010;212:252–259. doi: 10.1016/j.atherosclerosis.2010.05.022. [DOI] [PubMed] [Google Scholar]
  • 13.Suzuki M, O’Neal RM. Circulating lipophages, serum lipids, and atherosclerosis in rats. Arch Pathol. 1967;83:169–174. [PubMed] [Google Scholar]
  • 14.Rajavashisth T, Qiao JH, Tripathi S, Tripathi J, Mishra N, Hua M, Wang XP, Loussararian A, Clinton S, Libby P, Lusis A. Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in ldl receptor- deficient mice. J Clin Invest. 1998;101:2702–2710. doi: 10.1172/JCI119891. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Gerrity RG. The role of the monocyte in atherogenesis: I. Transition of blood- borne monocytes into foam cells in fatty lesions. Am J Pathol. 1981;103:181–190. [PMC free article] [PubMed] [Google Scholar]
  • 16.Swirski FK, Pittet MJ, Kircher MF, Aikawa E, Jaffer FA, Libby P, Weissleder R. Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc Natl Acad Sci U S A. 2006;103:10340–10345. doi: 10.1073/pnas.0604260103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 2003;19:71–82. doi: 10.1016/s1074-7613(03)00174-2. [DOI] [PubMed] [Google Scholar]
  • 18.Sunderkotter C, Nikolic T, Dillon MJ, Van Rooijen N, Stehling M, Drevets DA, Leenen PJ. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol. 2004;172:4410–4417. doi: 10.4049/jimmunol.172.7.4410. [DOI] [PubMed] [Google Scholar]
  • 19.An G, Wang H, Tang R, Yago T, McDaniel JM, McGee S, Huo Y, Xia L. P-selectin glycoprotein ligand-1 is highly expressed on ly-6chi monocytes and a major determinant for ly-6chi monocyte recruitment to sites of atherosclerosis in mice. Circulation. 2008;117:3227–3237. doi: 10.1161/CIRCULATIONAHA.108.771048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, Weissleder R, Pittet MJ. Ly-6chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest. 2007;117:195–205. doi: 10.1172/JCI29950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, Garin A, Liu J, Mack M, van Rooijen N, Lira SA, Habenicht AJ, Randolph GJ. Monocyte subsets differentially employ ccr2, ccr5, and cx3cr1 to accumulate within atherosclerotic plaques. J Clin Invest. 2007;117:185–194. doi: 10.1172/JCI28549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Wu H, Gower RM, Wang H, Perrard XY, Ma R, Bullard DC, Burns AR, Paul A, Smith CW, Simon SI, Ballantyne CM. Functional role of cd11c+ monocytes in atherogenesis associated with hypercholesterolemia. Circulation. 2009;119:2708–2717. doi: 10.1161/CIRCULATIONAHA.108.823740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Rudel LL, Kelley K, Sawyer JK, Shah R, Wilson MD. Dietary monounsaturated fatty acids promote aortic atherosclerosis in ldl receptor-null, human apob100-overexpressing transgenic mice. Arterioscler Thromb Vasc Biol. 1998;18:1818–1827. doi: 10.1161/01.atv.18.11.1818. [DOI] [PubMed] [Google Scholar]
  • 24.Zhang P, Boudyguina E, Wilson MD, Gebre AK, Parks JS. Echium oil reduces plasma lipids and hepatic lipogenic gene expression in apob100-only ldl receptor knockout mice. J Nutr Biochem. 2008;19:655–663. doi: 10.1016/j.jnutbio.2007.08.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Daugherty A, Whitman SC. Quantification of atherosclerosis in mice. Methods Mol Biol. 2003;209:293–309. doi: 10.1385/1-59259-340-2:293. [DOI] [PubMed] [Google Scholar]
  • 26.Furbee JW, Jr, Francone O, Parks JS. Alteration of plasma hdl cholesteryl ester composition with transgenic expression of a point mutation (e149a) of human lcat. J Lipid Res. 2001;42:1626–1635. [PubMed] [Google Scholar]
  • 27.Galkina E, Kadl A, Sanders J, Varughese D, Sarembock IJ, Ley K. Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially l-selectin dependent. J Exp Med. 2006;203:1273–1282. doi: 10.1084/jem.20052205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Tacke F, Ginhoux F, Jakubzick C, van Rooijen N, Merad M, Randolph GJ. Immature monocytes acquire antigens from other cells in the bone marrow and present them to t cells after maturing in the periphery. J Exp Med. 2006;203:583–597. doi: 10.1084/jem.20052119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Zampolli A, Bysted A, Leth T, Mortensen A, De Caterina R, Falk E. Contrasting effect of fish oil supplementation on the development of atherosclerosis in murine models. Atherosclerosis. 2006;184:78–85. doi: 10.1016/j.atherosclerosis.2005.04.018. [DOI] [PubMed] [Google Scholar]
  • 30.Asset G, Bauge E, Fruchart JC, Dallongeville J. Lack of triglyceride-lowering properties of fish oil in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol. 2001;21:401–406. doi: 10.1161/01.atv.21.3.401. [DOI] [PubMed] [Google Scholar]
  • 31.Wang HH, Hung TM, Wei J, Chiang AN. Fish oil increases antioxidant enzyme activities in macrophages and reduces atherosclerotic lesions in apoe-knockout mice. Cardiovasc Res. 2004;61:169–176. doi: 10.1016/j.cardiores.2003.11.002. [DOI] [PubMed] [Google Scholar]
  • 32.Xu Z, Riediger N, Innis S, Moghadasian MH. Fish oil significantly alters fatty acid profiles in various lipid fractions but not atherogenesis in apo e-ko mice. Eur J Nutr. 2007;46:103–110. doi: 10.1007/s00394-006-0638-3. [DOI] [PubMed] [Google Scholar]
  • 33.Wan JB, Huang LL, Rong R, Tan R, Wang J, Kang JX. Endogenously decreasing tissue n-6/n-3 fatty acid ratio reduces atherosclerotic lesions in apolipoprotein e-deficient mice by inhibiting systemic and vascular inflammation. Arterioscler Thromb Vasc Biol. 2010;30:2487–2494. doi: 10.1161/ATVBAHA.110.210054. [DOI] [PubMed] [Google Scholar]
  • 34.Phillipson BE, Rothrock DW, Connor WE, Harris WS, Illingworth DR. Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia. N Engl J Med. 1985;312:1210–1216. doi: 10.1056/NEJM198505093121902. [DOI] [PubMed] [Google Scholar]
  • 35.Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, Figueiredo JL, Kohler RH, Chudnovskiy A, Waterman P, Aikawa E, Mempel TR, Libby P, Weissleder R, Pittet MJ. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science. 2009;325:612–616. doi: 10.1126/science.1175202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Drechsler M, Megens RT, van Zandvoort M, Weber C, Soehnlein O. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation. 2010;122:1837–1845. doi: 10.1161/CIRCULATIONAHA.110.961714. [DOI] [PubMed] [Google Scholar]
  • 37.Ali K, Middleton M, Pure E, Rader DJ. Apolipoprotein e suppresses the type i inflammatory response in vivo. Circ Res. 2005;97:922–927. doi: 10.1161/01.RES.0000187467.67684.43. [DOI] [PubMed] [Google Scholar]
  • 38.Wientgen H, Thorngate FE, Omerhodzic S, Rolnitzky L, Fallon JT, Williams DL, Fisher EA. Subphysiologic apolipoprotein e (apoe) plasma levels inhibit neointimal formation after arterial injury in apoe-deficient mice. Arterioscler Thromb Vasc Biol. 2004;24:1460–1465. doi: 10.1161/01.ATV.0000134297.61979.3c. [DOI] [PubMed] [Google Scholar]
  • 39.Dyerberg J, Bang HO. Lipid metabolism, atherogenesis, and haemostasis in eskimos: The role of the prostaglandin-3 family. Haemostasis. 1979;8:227–233. doi: 10.1159/000214314. [DOI] [PubMed] [Google Scholar]
  • 40.Harris WS, Connor WE, Inkeles SB, Illingworth DR. Dietary omega-3 fatty acids prevent carbohydrate-induced hypertriglyceridemia. Metabolism. 1984;33:1016–1019. doi: 10.1016/0026-0495(84)90230-0. [DOI] [PubMed] [Google Scholar]
  • 41.De Caterina R, Cybulsky MI, Clinton SK, Gimbrone MA, Jr, Libby P. The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. Arterioscler Thromb. 1994;14:1829–1836. doi: 10.1161/01.atv.14.11.1829. [DOI] [PubMed] [Google Scholar]
  • 42.Casos K, Saiz MP, Ruiz-Sanz JI, Mitjavila MT. Atherosclerosis prevention by a fish oil-rich diet in apoe(−/−) mice is associated with a reduction of endothelial adhesion molecules. Atherosclerosis. 2008;201:306–317. doi: 10.1016/j.atherosclerosis.2008.02.033. [DOI] [PubMed] [Google Scholar]
  • 43.Adan Y, Shibata K, Ni W, Tsuda Y, Sato M, Ikeda I, Imaizumi K. Concentration of serum lipids and aortic lesion size in female and male apo e-deficient mice fed docosahexaenoic acid. Biosci Biotechnol Biochem. 1999;63:309–313. doi: 10.1271/bbb.63.309. [DOI] [PubMed] [Google Scholar]
  • 44.Roach PD, Kambouris AM, Trimble RP, Topping DL, Nestel PJ. The effects of dietary fish oil on hepatic high density and low density lipoprotein receptor activities in the rat. FEBS Lett. 1987;222:159–162. doi: 10.1016/0014-5793(87)80211-9. [DOI] [PubMed] [Google Scholar]
  • 45.Lindsey S, Pronczuk A, Hayes KC. Low density lipoprotein from humans supplemented with n-3 fatty acids depresses both ldl receptor activity and ldlr mrna abundance in hepg2 cells. J Lipid Res. 1992;33:647–658. [PubMed] [Google Scholar]
  • 46.Linga V, Leight MA, St Clair RW, Parks JS. Dietary fish oil modification of cynomolgus monkey low density lipoproteins results in decreased binding and cholesteryl ester accumulation by cultured fibroblasts. J Lipid Res. 1993;34:769–778. [PubMed] [Google Scholar]
  • 47.Choi SY, Fong LG, Kirven MJ, Cooper AD. Use of an anti-low density lipoprotein receptor antibody to quantify the role of the ldl receptor in the removal of chylomicron remnants in the mouse in vivo. J Clin Invest. 1991;88:1173–1181. doi: 10.1172/JCI115419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Swirski FK, Weissleder R, Pittet MJ. Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:1424–1432. doi: 10.1161/ATVBAHA.108.180521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Potteaux S, Gautier EL, Hutchison SB, van Rooijen N, Rader DJ, Thomas MJ, Sorci-Thomas MG, Randolph GJ. Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of apoe−/− mice during disease regression. J Clin Invest. 2011;121:2025–2036. doi: 10.1172/JCI43802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med. 2008;359:2195–2207. doi: 10.1056/NEJMoa0807646. [DOI] [PubMed] [Google Scholar]
  • 51.Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6:1399–1402. doi: 10.1038/82219. [DOI] [PubMed] [Google Scholar]
  • 52.Becker L, Gharib SA, Irwin AD, Wijsman E, Vaisar T, Oram JF, Heinecke JW. A macrophage sterol-responsive network linked to atherogenesis. Cell Metab. 2010;11:125–135. doi: 10.1016/j.cmet.2010.01.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Yancey PG, Ding Y, Fan D, Blakemore JL, Zhang Y, Ding L, Zhang J, Linton MF, Fazio S. Low-density lipoprotein receptor-related protein 1 prevents early atherosclerosis by limiting lesional apoptosis and inflammatory ly-6chigh monocytosis: Evidence that the effects are not apolipoprotein e dependent. Circulation. 2011;124:454–464. doi: 10.1161/CIRCULATIONAHA.111.032268. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

RESOURCES